<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116120">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02075268</url>
  </required_header>
  <id_info>
    <org_study_id>PRAS-AM</org_study_id>
    <secondary_id>2014-0064</secondary_id>
    <nct_id>NCT02075268</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Characterize Pharmacokinetic-pharmacodynamic (PKPD) of Prasugrel 10 mg or 30 mg in Healthy Volunteers</brief_title>
  <acronym>PRAS-AM</acronym>
  <official_title>An Open Label, Single Dose Study to Characterize the Pharmacokinetics and Pharmacodynamics of Prasugrel in Healthy Male Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label, parallel study to characterize the pharmacokinetics and pharmacodynamics of
      Prasugrel 30 mg or 60 mg in healthy male adult subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Screening

        2. Enrollment and treatment randomization

        3. Confinement to Research Unit from day - 1 to day 2

        4. Outpatient visit : 2 times ( 48 and 73 hours after dosing)

        5. Drug administration : Overnight Fasting

        6. Blood sampling for PK, PD and genotyping

             1. PK: up to 24 hours after dosing

             2. PD: up to 72 hours after dosing
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>plasma R-138727 and R-95913 concentrations</measure>
    <time_frame>predose, 10 min, 15 min, 25 min, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 4 h, 6 h, 8 h, 12 h and 24 h after dosing</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal platelet aggregation</measure>
    <time_frame>predose, 15 min, 0.5 h, 1 h, 2 h, 4 h, 8 h, 24 h, 48 h and 72 h after dosing</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximal platelet aggregation will be measured by light transmission test</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>10 mg, 30 mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>To compare PKPD of prasugrel 10 or 30 mg, 4 subjects will be given 10 mg of prasugrel (one tablet of 10 mg of Effient) on day 1 as a single oral dose and another 4 subjects will be given 30 mg of prasugrel (3 tablets of 10 mg of Effient) on day 1 as a single oral dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prasugrel</intervention_name>
    <description>prausugrel 10 or 30 mg will be administrated as single dose under overnight fast.</description>
    <arm_group_label>10 mg, 30 mg</arm_group_label>
    <other_name>Effient 10 mg tablet will be used as study drug.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male aged 19 to 45 years

          -  weigh  over 60 kg

          -  body mass index 18 to 30 kg/m2

        Exclusion Criteria:

          -  any history or state of clinically significant disease

          -  any gastrointestinal disease may interfere absorption of drug

          -  any history of hypersensitivity to prasugrel or other drug

          -  any history of taking herbal medication within 30 days before dosing or taking
             prescription medication within 14 days before dosing or taking over the counter drug
             within 7 days before dosing

          -  taking investigational drug within 60 days before dosing

          -  transfused within 30 days or  donated blood within 60 days before dosing

          -  Positive serology test ( Hepatitis B surface antigen (HBs Ag), HIV, HCV)

          -  Clinically significant finding in laboratory result or electrocardiogram result
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MI Jo Kim, MD</last_name>
      <phone>82-2-3010-4622</phone>
      <email>mjk0326@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hyeong-Suk Lim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 28, 2014</lastchanged_date>
  <firstreceived_date>February 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Hyeong-Seok Lim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Korean</keyword>
  <keyword>Healthy</keyword>
  <keyword>Male</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prasugrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
